Welcome to our dedicated page for Cabot SEC filings (Ticker: CBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Specialty chemical companies like Cabot Corporation produce SEC filings that reveal segment profitability, raw material cost impacts, and geographic revenue distribution. Understanding how carbon black demand correlates with automotive cycles requires examining quarterly 10-Q reports that break down Reinforcement Materials and Performance Chemicals results separately.
Cabot's 10-K annual reports detail the company's two operating segments with granular information on manufacturing capacity, customer concentration, and competitive positioning. The filings explain how tire manufacturer demand, feedstock pricing, and regional production costs affect margins. Performance Chemicals disclosures cover specialty carbons, fumed silica, and battery materials—each with distinct market dynamics.
Our AI-powered summaries extract the critical numbers from Cabot's regulatory documents. Instead of searching through accounting footnotes for segment operating income or capacity utilization metrics, get simplified explanations of what each filing reveals about the company's chemical operations.
Form 4 insider trading filings track when Cabot executives and directors buy or sell shares. These transactions, combined with proxy statement (DEF 14A) disclosures on executive compensation, provide insight into management's perspective on company value. Monitor insider activity patterns alongside quarterly results.
Material event filings (8-K) cover acquisition announcements, leadership changes, dividend declarations, and other developments requiring immediate disclosure. Cabot's 8-K filings often accompany earnings releases and provide supplemental financial data.
Access Cabot Corporation's complete SEC filing history with AI explanations that simplify complex chemical industry disclosures and highlight the information investors need for specialty materials analysis.
Cabot Corporation director Juan Enriquez reported an acquisition of company stock through a compensation-related transaction. On January 8, 2026, he acquired 486 shares of Cabot common stock at a price of $0 per share, reflecting equity granted rather than an open-market purchase. The filing notes that these shares have been deferred under Cabot's Non-Employee Directors' Deferral Plan, meaning the director has chosen to defer receipt of the shares according to that plan's terms. Following this transaction, Enriquez beneficially owns 41,526 Cabot common shares, held directly.
Cabot Corporation director Raffiq Nathoo reported acquiring 2,298 shares of Cabot common stock on January 8, 2026. The filing shows the shares were credited at a price of $0 per share and were deferred under Cabot's Non-Employee Directors' Deferral Plan, meaning they reflect deferred director compensation rather than an open-market purchase. Following this transaction, Nathoo beneficially owned 9,266 Cabot shares, held directly.
Cabot Corporation director Doug G. Del Grosso reported acquiring 2,298 shares of Cabot common stock on January 8, 2026. The shares were recorded at a price of $0.00 per share, indicating they were received without cash consideration, such as through an equity award or similar arrangement. Following this transaction, Del Grosso directly holds 15,079 shares of Cabot common stock. The filing indicates the transaction was made by a single reporting person in his capacity as a director.
Cabot Corporation director Thierry Vanlancker reported an acquisition of company common stock through a compensation-related deferral. On January 8, 2026, he acquired 2,298 shares of Cabot common stock at a stated price of $0 per share, classified as an acquisition transaction. After this transaction, he beneficially owned 4,902 Cabot shares in total, held directly.
According to the footnote, these shares have been deferred under Cabot's Non-Employee Directors' Deferral Plan, meaning they arise from the director compensation program rather than an open‑market purchase. The filing indicates this report is made by a single reporting person in his capacity as a director of Cabot Corporation.
Cabot Corporation director reports stock award under deferral plan. Director Michelle Elizabeth Williams acquired 2,298 shares of Cabot Corporation common stock on January 8, 2026, reported as an award at a price of $0 per share. Following this award, she beneficially owned 6,776 shares of Cabot common stock in total.
The filing notes that these shares have been deferred under Cabot's Non-Employee Directors' Deferral Plan, meaning the award is subject to the terms of that plan rather than delivered as immediately unrestricted shares.
Cabot Corporation director Michael M. Morrow reported an acquisition of company common stock under a director compensation arrangement. On January 8, 2026, he acquired 2,298 shares of Cabot common stock at a reported price of $0 per share, reflecting stock granted rather than purchased for cash. Following this transaction, he beneficially owned 22,302 shares of Cabot common stock in direct form.
The filing notes that these shares have been deferred under Cabot's Non-Employee Directors' Deferral Plan, meaning the value is credited for the director’s benefit instead of being immediately delivered in standard shares. The transaction reflects routine director equity compensation rather than an open-market trade.
Cabot Corporation director Christine Y. Yan reported receiving 2,298 shares of Cabot common stock on January 8, 2026, as an acquisition transaction. The shares were credited at a price of $0.00 per share under Cabot's Non-Employee Directors' Deferral Plan, meaning they represent deferred director compensation rather than an open-market purchase. Following this transaction, Yan beneficially owned 17,171 shares of Cabot common stock in direct form. This filing reflects routine equity-based compensation for a non-employee director rather than a cash trade in the stock.
Cabot Corporation director Frank Anders Wilson reported an acquisition of company stock under a deferred compensation arrangement. On January 8, 2026, he acquired 2,298 shares of Cabot common stock at a stated price of $0 per share, bringing his directly held beneficial ownership to 18,552 shares. The filing explains that these shares have been deferred pursuant to Cabot's Non-Employee Directors' Deferral Plan, meaning the award is tied to his service as a non-employee director rather than an open-market purchase.
Cabot Corporation director Cynthia A. Arnold reported acquiring additional company stock. On January 8, 2026, she acquired 2,298 shares of Cabot common stock in a transaction reported with a price of $0 per share, indicating the shares were received without cash payment, such as through an award or similar arrangement. Following this transaction, she beneficially owns 19,620 shares of Cabot common stock, held directly in her name.
Cabot Corporation director William C. Kirby reported an acquisition of 486 shares of Cabot common stock on January 8, 2026, at a price of $0 per share. These shares were acquired as a form of compensation rather than through an open-market purchase, and are linked to Cabot's Non-Employee Directors' Deferral Plan. Following this transaction, Kirby beneficially owned 27,688 shares of Cabot common stock in direct form.
The filing characterizes this as a non-derivative, compensation-related award, reflecting ongoing equity-based alignment between the director and the company.
FAQ
What is the current stock price of Cabot (CBT)?
What is the market cap of Cabot (CBT)?
